CDC Lowers Age for Pneumococcal Vaccination from 65 to 50
Lowering the age gives more adults the opportunity to protect themselves from pneumococcal disease at an age when the risk of infection increases, according to the CDC.
Tag: Merck
All
Latest
CDC Lowers Age for Pneumococcal Vaccination from 65 to 50
Lowering the age gives more adults the opportunity to protect themselves from pneumococcal disease at an age when the risk of infection increases, according to the CDC.
Read More
Merck Stops Late-Stage Trial of Vibostolimab-Pembrolizumab Combo in Small Cell Lung Cancer
The phase 3 trial was investigating the vibostolimab and pembrolizumab combination with chemotherapy for first-line treatment of extensive-stage small cell lung cancer.
Read More
Merck’s Investigational RSV Shot Protects Infants in Phase 2b/3 Trial
The trial showed that clesrovimab reduced RSV-related respiratory infections in infants through day 150.
Read More
USDA Approves First RNA-Based Dog Flu Vaccine
A new RNA-based vaccine approved by the USDA offers protection against the year-round threat of canine influenza.
Read More
FDA Approves Merck’s Pneumococcal Vaccine for Adults
The vaccine covers serotypes responsible for approximately 84% of invasive pneumococcal disease in adults 50 years of age and older.
Read More
FDA Approves Merck’s Injection for Pulmonary Arterial Hypertension
The injection on top of background therapy significantly improved exercise capacity and multiple secondary outcome measures compared to background therapy alone.
Read More
FDA Grants Priority Review to Merck’s Pneumococcal Conjugate Vaccine for Adults
The FDA accepted for priority review a new Biologics License Application for V116, Merck’s investigational 21-valent pneumococcal conjugate vaccine designed to help prevent invasive pneumococcal disease and pneumococcal pneumonia in adults.
Read More
Merck’s COVID Drug May be Causing the Virus to Mutate
Researchers identified unusual COVID-19 mutation patterns that were strongly associated with molnupiravir use and coincided with the drug’s introduction.
Read More
Ebola Vaccine Approved in Children Age 1 and Older
The FDA approved an expanded indication for Merck’s Ervebo vaccine, which is now indicated for the prevention of disease caused by Zaire ebolavirus in individuals 12 months of age and older.
Read More
Gefapixant Gets European Medicines Agency’s Backing for Chronic Cough
Merck’s investigational drug for chronic cough is one step closer to coming to market after receiving a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use.
Read MoreFDA Green-lights Merck’s MMRV Vaccines for Intramuscular Injection
With these approvals, healthcare professionals now have the option to administer Merck’s measles, mumps, rubella, and varicella vaccines intramuscularly.
Read More
Merck’s Keytruda Meets Primary Endpoint in Phase 3 Trial for Lung Cancer
The US Food and Drug Administration has accepted Merck’s new supplemental Biologics License Application based on data from the trial.
Read More
FDA Approves Vaxneuvance Pneumococcal Vaccine for Infants, Children
The FDA has expanded the approval for Merck’s Vaxneuvance for prevention of invasive disease caused by Streptococcus pneumoniae to include children 6 weeks through 17 years of age.
Read More
FDA Authorizes Merck Molnupiravir Antiviral COVID Pill
The FDA issued emergency authorization for Merck’s molnupiravir for the treatment of mild-to-moderate COVID-19 in adults age 18 and older with positive results of direct SARS-CoV-2 viral testing.
Read More
Merck VaxNeuvance Pneumococcal Vaccine Approved in EU
The European Commission approved Merck’s VaxNeuvance (Pneumococcal 15-valent Conjugate Vaccine) for prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals 18 years of age and older.
Read More
Success of COVID Antiviral Pills Hinges on Access to Speedy and Accurate Tests
Experts say the success of COVID Antiviral Pills depends on whether high-risk patients will be able to get tested, and then treated, fast enough to make a difference.
Read More
Merck to License COVID-19 Antiviral to Drugmakers in Other Companies
Merck has entered into a voluntary licensing agreement to allow the production of its investigational COVID-19 antiviral molnupiravir by drugmakers in 105 low- and middle-income countries.
Read More
Merck’s COVID-19 Antiviral Pill Cut Prevented Mortality, Cut Hospitalization Risks in Half
Merck’s COVID-19 antiviral molnupiravir reduced the risk of hospitalization or death by approximately 50% compared to placebo.
Read More
FDA: New Merck Pneumonia Vaccine OK’d
The FDA approved a new pneumonia vaccine from Merck, according to a report from the Boston Herald.
Read More
Merk’s Experimental Lung Cancer Drug Fails Trial
Merck KGaA’s experimental lung cancer treatment bintrafusp alfa failed in an early trial, the company recently announced.
Read More
Positive Data for Merck’s Pneumococcal Conjugate Vaccine Candidate
Two Phase 3 studies of Merck’s investigational 15-valent pneumococcal conjugate vaccine met their primary immunogenicity objectives.
Read More
FDA Slaps Black Box Warning on Singulair over Serious Mental Health Side Effects
“Because of the risk of mental health side effects, the benefits of montelukast may not outweigh the risks in some patients, particularly when the symptoms of disease may be mild and adequately treated with other medicines,” the FDA said.
Read More
Foradil Aerolizer to be Discontinued
The FDA says Novartis and Merck have jointly decided to voluntarily discontinue manufacture of Foradil Aerolizer “for business reasons.”
Read More
Merck’s Sublingual Allergen Ragwitek Approved By FDA For Ragweed Allergies
The FDA has approved Ragwitek, a sublingual allergen extract to treat short ragweed pollen induced allergic rhinitis (hay fever) in adults 18 years through 65 years of age.
Read More